Cancer Immunotherapy Applications
-
Microbiome Therapeutics for Patients and Physicians
Seres’ microbiome therapeutics represent a transformative new approach to ...
By Seres Therapeutics, Inc. based in Cambridge, MASSACHUSETTS (USA).
-
Next generation immune sequencing for infectious disease
Data from examining the immune repertoire of cancer patients can be used to identify patterns associated with positive outcomes and monitor the progress of immunotherapies in clinical trials. Single cell immune sequencing technologies provide an even more granular view of individual T cell or B cell populations following immunotherapy, providing unprecedented detail for informing cancer ...
By iRepertoire, Inc. based in Huntsville, ALABAMA (USA).
-
RNA Technology for Medical Areas of Focus Research
Using our platform, we are developing mRNA medicines for diverse uses and delivering them to patients across the globe. We are currently focusing on 4 medical areas - infectious diseases, immuno-oncology, rare diseases and autoimmune ...
By Moderna, Inc. based in Cambridge, MASSACHUSETTS (USA).
-
Antibody Discovery
The antibody drug discovery process differs from the traditional drug discovery of small molecules as it requires the development of hybridomas and the engineering of antibodies to recognize a specific target protein. The production of recombinant antibodies in cancer treatment as well as the development of neutralizing antibodies for infectious diseases, has allowed antibody discovery platforms to interrogate the immune repertoire and develop novel antibody libraries using flow cytometry analysis and cell ...
By NanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA).
-
Ativa - Diagnostic Workstation for Covid-19
ATIVA’s rapid low-cost COVID-19 test may provide earlier detection and a safer community. The greatest challenge we face is the spread of infection before symptoms appear. We all want to protect our loved ones, so how do we know if we are carrying the virus? Physical symptoms (fever, cough) appear too late to stop the spread. The nasal swab PCR tests suffer from sampling errors, slow time to results, and are expensive. Early detection of infected people is the key to protecting our most vulnerable people in ...
By Ativa Medical based in Shoreview, MINNESOTA (USA).
-
NK-cell Therapy - Ushering in the Future of NK-cell Therapy
Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce cancer cell death and even help trigger a broader adaptive immune ...
By Kiadis Pharma NV based in Amsterdam, NETHERLANDS.
-
Highly customized aptamer discovery solutions for therapeutic aptamers sector
As targeted therapies evolve and the limitations of antibody-based therapies become clearer, a growing number of research teams are exploring the therapeutic potential of ...
By Base Pair Biotechnologies, Inc. based in Pearland, TEXAS (USA).
-
IGX Platform Software for Cancer Vaccines
Unlike conventional vaccination strategies, cancer vaccines are designed to mount responses against tumor-specific antigens, arising from somatic mutations specific to the cancer genome. They promise a highly tailored approach by targeting patient-specific ...
By Enpicom B.V. based in s-Hertogenbosch, NETHERLANDS.
-
Temferon: Adding Interferon to TEMs
We have developed proprietary methods for expressing immunotherapeutic payloads in a highly controlled and specific manner within tumors. IFN-α is a well-known therapeutic that was previously administered systemically for treatment of various cancers but it is currently rarely used because of its systemic toxicity. In the tumor microenvironment, IFN-α exerts its anti-tumor activity both directly by promoting cancer cell apoptosis and inhibiting vascularization and indirectly by restoring anti-tumor ...
By Genenta Science based in Milano, ITALY.
-
Proprietary Technologies for Approach Towards Cancer
With the development and commercialization of immunotherapy drugs such as checkpoint inhibitors, the field of immuno-oncology is transforming the treatment of patients with cancer. However, cures remain elusive, and many cancer patients experience only modest clinical ...
By Gritstone Bio based in Emeryville, CALIFORNIA (USA).
-
TCR and BCR insights for immuno-oncology industry
Data from examining the immune repertoire of cancer patients can be used to identify patterns associated with positive outcomes and monitor the progress of immunotherapies in clinical trials. Single cell immune sequencing technologies provide an even more granular view of individual T cell or B cell populations following immunotherapy, providing unprecedented detail for informing cancer ...
By iRepertoire, Inc. based in Huntsville, ALABAMA (USA).
-
Solutions for benchtop single cell sorting and dispensing sector
High Performance Across the Breadth of Biotech. The NX One is a perfect fit for a wide variety of sectors and application areas spanning fundamental biological research to industrial and clinical workflows. Access your cells faster and at a fraction of the ...
By Nodexus Inc. based in Hayward, CALIFORNIA (USA).
-
Immunoscore for Colon Cancer Patients
To date, the classification of cancers has been based solely on the phenotypic and genotypic characteristics of tumor cells. A new paradigm, scientifically well established and recommended by WHO guidelines, relies on the introduction of the immune response as a new prognostic parameter to predict and refine the clinical outcomes of cancer patients. Maximize patient survival rates with an assessment of the tumor immune response. ...
By Veracyte based in Marseille Cedex 9, FRANCE.
-
RNA Technology for Product Pipeline Research
Our product pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions. We are proud of the advancements we’ve made in pioneering new mRNA vaccines and treatments that may have the potential to treat and prevent rare ...
By Moderna, Inc. based in Cambridge, MASSACHUSETTS (USA).
-
Immunoscore for IC in Lung Cancer
IMMUNOSCORE® IC is intended for the detection of PD-L1 protein and the concomitant detection of CD8 + cells in Non-Small Cell Lung cancer (NSCLC) ...
By Veracyte based in Marseille Cedex 9, FRANCE.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you